Efficacy of Low Dose Denosumab in Maintaining Bone Mineral Density in Postmenopausal Women With Osteoporosis Switching From 60mg to 30mg 6 Monthly: A Real World, Prospective Observational Study

Introduction: Denosumab, a fully human monoclonal antibody to RANK-ligand, has been shown to increase bone mineral density (BMD) and reduce the risk of fracture in postmenopausal women with osteoporosis. Cessation of denosumab is associated with rises in bone remodelling, reductions in BMD and an in...

Full description

Saved in:
Bibliographic Details
Published in:J Endocr Soc
Main Authors: Khan, Aliya, Alrob, Hajar Abu, Said, Hosay, Iqbal, Salman, Hweija, Ismail, Hussain, Sharjil
Format: Artigo
Language:Inglês
Published: Oxford University Press 2021
Subjects:
Bone and Mineral Metabolism
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC8090192/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/jendso/bvab048.489
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items